Skip to main content

ACR 2026 RheumNow RA Topic Compilation a

Nov 17, 2026 10:43 am
Can a smartphone identify inflammatory arthritis GLP-1 A game changer for lung health Menopause in RA An Under Recognized Burden JAK vs TNFi in RA Can Biomarkers Help us Choose JAK1 TYK2i beats Tofacitinib in Active RA Rosnilimab in RA Why May it be Relatively Safe Can Gut Candida Trigger Rheumatoid Arthritis Maybe Head to Head JAK vs JAK in RA Fibromyalgia and Depression in Rheumatoid Arthritis A New Way to Measure Disease Activity in Rheumatoid Arthritis Study Design and Comparative Effectiveness in RA GLP-1 Drugs in Osteoarthritis and Rheumatoid Arthritis

Transcription

This is an ACR twenty twenty six podcast coming to you from ACR in Orlando. Hope you enjoy it. Great rheumatologists go to great meetings like this. RoomNow live twenty twenty seven is happening January 3031 in Dallas, Texas. Join your colleagues from across the country and around the world for an interactive, engaging, and practice changing event.

Go to rheumnow.live to see the full program and register today.

Mindful of that.

Hi. This is Bella Mehta from RheumNow reporting from ACR twenty six. And this is a very interesting abstract on 1869 that I found. And this is looking at if if just hand photographs from any smartphone can identify cyanosis. I mean, isn't that the key question in rheumatology?

Can can some... Can there be an easy reproducible way to to figure out if patients have swelling? So what these patients... The... What these people did is got a thousand patients ordinary hand photographs taken

from

a smartphone and compared it with joint counts from a rheumatologist as well as ultrasound. And the sensitivity was 80%, specificity of 70%, and the negative predictive value was around 98%. So... To... And this will help find a fusion, and there was a robust external validation, especially with the study.

And when we use ultrasound defined synovitis as a reference, instead of the joint counts only, the sensitivity did increase to around 89%. So now with computer vision and AI getting these pictures from ordinary, know, day to day life, have, you know, we can now diagnose these patients or at least get them the right help even early on. So, you know, these could be patients who have... Rule out inflammatory arthritis even before they actually reach a doctor. So, again, this will help reshape rheumatology, I think, if we can do this right and can do this in practice long term.

So with that, signing off. This is Bella Mehta from RheumNow. Follow me on Twitter, Bella underscore Mehta. Thank you.

GLP one, a game changer for lung health rheumatoid arthritis. Here's Lisa Mota reporting for you now from Orlando, ACR twenty twenty six. Well, abstract fourteen forty five presented by Evis and colleagues brings some Trigen findings. Using the TRiNet X database, researchers compared GLP-one receptor agonist with DPP-four inhibitor in patients with rheumatoid arthritis and type two diabetes. After propensity score matching, more than 3,000 patients were included with three years of follow-up and the results were striking.

GLP-one receptor agonist use was associated with a fifty three percent lower hazard of pulmonary hypertension And more than this, there was also forty five percent lower hazard of mechanical ventilation, a twenty five percent lower hazard of respiratory failure, and a thirty one percent lower hazard of all cause mortality. So, this is very important, but here's the twist. Despite these encouraging pulmonary outcomes, there was no significant association with incident interstitial lung disease. So, RGLP1 receptor agonists improve in pulmonary outcomes without actually preventing IOD. And could these benefits reflect metabolic improvements, cardiovascular effect or even direct pulmonary mechanisms?

Of course, this was a retrospective observational study, so we cannot establish causality. The bottom line of this study is that GLP-one receptor agonists may offer benefits beyond metabolic control in rheumatoid arthritis. But whether they are truly a preliminary game changer remains an open question. So stay tuned for more.

Hi, my name is Akhilsod reporting for RheumNow. Suppose you have your patient with rheumatoid arthritis returning for follow-up. After starting DMARR therapy, you've noticed significant improvement. Reduced tender joints, reduced swollen joints, and improved morning stiffness. But your patient's still complaining of ongoing fatigue, poor sleep, and aching pains in the muscle and joints.

Have you considered menopause? After 1849, seeks to explore this. By using a large database, a patient seen at Mayo of women ages 40 to 65, they quantified and compared the severity of menopause in women with RA versus without rheumatoid arthritis. And menopause severity was was scored using the menopause rating scale, which is a validated tool that encompasses different domains, including somatic, psychological, and urogenital symptoms. And among ninety four patients, nine thousand four hundred participants, about two percent had rheumatoid arthritis.

Rheumatoid arthritis patients were older on average, and obesity was more common. And hormone replacement therapy in SSRI and SNRI use were similar in both groups. And among women with RA, the severity of symptoms in menopause were higher compared to women without RA. And additionally, severity of hot flashes were higher among women with rheumatoid arthritis versus those without. And these associations were significant.

And so what can we take from this? Menopause is prevalent in women with RA, and it is likely an under recognized burden in patients with rheumatoid arthritis. But it's important to consider that this is a cross sectional study. We need longer term follow-up to better evaluate the relationship between rheumatoid arthritis and the severity of menopause symptoms. It's also possible that many symptoms of rheumatoid arthritis can overlap with menopause as well.

And so when it comes back to the clinic, it's important to consider is the disease under control and what's driving these ongoing symptoms. And by thinking of other potential causes such as menopause, this can open the conversation about other tools we can use to better serve our patients. My name is Akhil Sood reporting for MEL. Thank you.

Check inhibitors versus TNF inhibitors. Can biomarkers help us choose? I'm Alicia Mota, rheumatologist from University of Brasilia, reporting for RheumNow from, Orlando at the ACR twenty twenty six. Well, if we have very similar patients with a very similar diagnosis of rheumatoid arthritis, why do they answer so differently to the same treatment? And importantly, could biomarkers help us choose what would be the best treatment?

Abstract twenty twenty nine explored exactly this question. So researchers from Spain study immune cells from forty eight patients with rheumatoid arthritis, exposing them ex vivo to baricitinib or etanercept. And they evaluated 92 inflammatory proteins and then tested their molecular signatures in clinical cohorts, including two twenty three patients. And here is the interesting part. Although both treatments affected immune cells profiles, they produce distinct proteomic signatures.

So patients with higher expression of the JAK related signature had better outcomes with JAK inhibition. And similarly, those with higher expression of the TNF related signature responded better to TNF inhibition. And a certain protein model predicted six months remission with AUC of 0.75 in patients not previously exposed to target therapies. But, in previously treated patients, the AUC dropped to just 0.57. To me, this is a particularly important finding because it reminds us that rheumatoid arthritis is not only clinically heterogeneous.

It's also molecularly very, very heterogeneous. But are we ready to use this approach in everyday practice? No. Not yet. We still need a prospective validation and safe comorbidities and patient choices really, really matters.

The take home message of this study is that it brings us one step closer to moving beyond trial and error at our precision medicine in rheumatoid arthritis. I'm Lisa Motta reporting for RheumNow.

Hi. I'm doctor Janet Pope tweeting as Janet Bordeaux as part of the RheumNow, family of reporters at American College of Rheumatology twenty twenty six convergence meeting in Orlando, Florida. I want to talk about a late breaking abstract because I have some questions about this. The question that we would have is do we need another JAK inhibitor, and if so, is it gonna have an added value? We know there's a family of JAK inhibitors.

There's JAK one, two, three. They can be paired, and there's TIC two, and TIC two can be on its own or paired with things like JAK one and other pairs, beyond the JAK family. So is this just another JAK or not? So there was a phase three randomized controlled trial in active RA who had failed one or more biological DMARDs, so inadequate responders, a twenty four week trial. They looked at, girocitinib, which is a JAK one, tick two inhibitor, oral, of course, versus tofacitinib, which we think in general is a JAK one inhibitor.

So it was a head to head RCT over twenty four weeks. Primary outcome was an ACR 50. In general, in head to head trials of both active drugs, you will get high ACR fifties, but you should get them relatively high in all groups. So the ACR 50 of tofacitinib was 49.5, so very high as we would expect in a head to head trial. But the ACR 50 of gericidenib, the JAK1 TYK2 inhibitor, was extremely high, seventy three percent.

Or if you don't wanna remember the numbers, three quarters got an ACR 70... ACR 50, in giversidenib and one half in tofasidenib. They also looked at the other secondary endpoints, c d I less than or equal to 10, other ACR responses, etcetera. And, basically, this replicated the phase two trial results that were presented a couple years ago or a few years ago, and always favoring gericitinib. So the safety was similar, although it was only a twenty four week trial.

So what is our take home here? Our take home is that this is not just another JAK, that in this case, a JAK one, tick two is superior to a JAK alone. But my questions are, will these results be replicated beyond China? The, drug development so far has only involved, patients in China, and time will tell. Please follow us at RheumNow.

Thank you.

Hello. I'm Jonathan Kaye from UMass Chan Medical School in Worcester, Massachusetts reporting for RheumNow from ACR Convergence twenty twenty six in Orlando, Florida. At the plenary session on Sunday, the first day of the meeting, Cos Petsalis of Saint Bart's Hospital, Queen Mary, Medical School in London presented data about the translational, studies associated with the rosnilimab, clinical trial. Rosnilimab is an antibody against PD one and was studied and presented last year at ACR Convergence twenty twenty five as a late breaking abstract where there were positive results from the phase two b study. In this study, rozanolimab was given either one hundred milligrams or four hundred milligrams every four weeks or six hundred milligrams every two weeks, and patients were followed for twelve weeks in a placebo controlled period.

Patients were then continued on active drug, and the two highest doses were effective, and more effective than placebo in that, placebo controlled twelve week period. Doctor Pitzalis presented the translational data which showed that there was depletion of PD one high, t cells, t peripheral helper cells, in patients treated with the two highest doses, but no reduction in total t cells or in t regulatory cells. There was also a decrease in pro inflammatory cytokines, I l six, CXCL 13, and m c p three. So this medication depletes selectively those pathogenic T peripheral helper cells while not depleting total T cells or T regulatory cells, resulting in a relatively safe clinical profile, at least in phase two b. This is an interesting explanation to justify the observation that the safety profile seemed quite good with a good efficacy profile.

Now remember, this is phase two b, and oftentimes phase two is rather encouraging. And then in a larger placebo controlled phase three trial, results are not necessarily as robust. But we look forward to seeing the phase three development of rozanolimab, and further data about this and other molecules at ACR convergence twenty twenty six in Orlando, Florida. I'm Jonathan Kaye reporting for RheumNow. For more on this and other things, go to rheumnow.com.

Hi. I'm doctor Janet Pope. I'm a rheumatologist and professor of medicine at Western University, London, Canada. I tweet as at Janet Broudhope, and I'm here as part of the RheumNow group, covering the meeting, ACR twenty twenty six in sunny Orlando, Florida. I wanted to talk about, an oral presentation abstract number two eight three two, and I thought it was one of our best abstracts of today so far.

So the idea is we know the microbiome is perturbed in just about any autoimmune disease, probably almost any disease, by treatment, by inflammation, by other things that might increase the chance of getting a disease. So the question here was could Candida albicans trigger rheumatoid arthritis? And this was out of the Denver group, and they have the early RA cohort. They also have the RA at risk patients, and they were able to do all that kind of look as well as looking in a mouse model. So first of all, Candida albicans can be increased in the microbiome of patients with RA and at risk RA, and this group showed it.

Also, we know in the gut that IgA for candida albicans and some other candida can be increased in these patients. So sort of a link that something's going on compared to controls. Also, if they looked at a mouse model and they gave Canada, to change the gut microbiome, it in and of itself was insufficient to cause inflammatory arthritis for the, mice that would be bred to be at risk for RA. But the idea was it could be silent immune priming to increase the risk of, inflammatory arthritis if something else occurs, maybe an infection, maybe a trauma, etc. So what they found was that in the mice they didn't get inflammatory arthritis until they were primed for something else after, but the Th seventeen pathway was altered.

They had very eloquent studies saying that if they blocked it, things would improve. If they upregulated it, it would worsen. So why did I choose this? First of all, I think there's probably almost as high as our microbiome of the number of studies of, the differences in patients with RA versus healthy controls. I chose it because I do think patients ask, you know, what causes, number one.

But number two, more importantly, could we intervene earlier to try to make a healthy gut microbiome for our at risk RA patients, and maybe they wouldn't develop RA, or for our RA patients who... In whom we're trying to treat to a target and they're not reaching it. So, hopefully, more will come in this field of research. I think the presentation was very well done. Please follow us at RheumNow.

Thank you.

Hello. I'm Jonathan Kaye from UMass Chan Medical School in Worcester, Massachusetts reporting for RheumNow from ACR Convergence twenty twenty six in Orlando, Florida. Today, there was a poster, late breaking poster 21 from China, which reported a phase three clinical trial, a head to head study comparing durasitinib, a JAK one, TIC two inhibitor, to tofacitinib, which is a relatively nonspecific JAK three one two inhibitor. This study, enrolled 459 subjects in China, one to one randomized to durasitinib or tofacitinib. Patients were largely seropositive, either with circulating rheumatoid factor or circulating IgG anti CCP antibodies.

High disease activity by C. Dye. Mean C. Dye was around 35. Patients had been on at least one biologic DMARD.

There were some patients who'd previously been on a JAK inhibitor, but were not taking JAK inhibitor for at least six weeks prior to entry into the study. The impressive result was that durasitinib was superior to tofacitinib with the primary endpoint being the ACR 50 at week twenty four, with about 76, ACR 50 with durasitinib, seventy three percent compared to fifty percent with tofacitinib. At each of the time points starting at one month, durasitinib was superior to tofacitinib with statistical significance at each time point. As in most studies that are conducted in China, there were relatively few adverse events reported, but adverse events were relatively evenly balanced, between the two groups. There was one, venous thromboembolism in a patient taking tofacitinib, no VTEs or MACE major adverse cardiovascular events with duracitinib.

So this is a phase three randomized active comparator clinical trial comparing duracitinib, a JAK one tick two selective, inhibitor to tofacitinib showing superiority at a threshold of an ACR 50 response, at twenty four weeks. This is very interesting, although the caveat of a study conducted in China, exclusively in China with relatively low reporting of adverse events should be repeated elsewhere. Looking forward to seeing more about this agent and more about everything else at room... At ACR Convergence twenty twenty six. For RheumNow, I'm Jonathan Kaye.

See you again at roomnow.com.

So the question is, why do seventy five percent of RA patients have either no swollen joints or one swollen joint, but only forty two to forty nine percent of patients are in C. Dye remission or low disease activity state. I think it's an interesting question posed by today's presentation by doctor Ted Pincus of Rush University abstract fourteen thirty five, where he talks about, the fact that if you screen an RA cohort as he has always done throughout his whole career, with the MDHAC survey tool that you'll find out not only about how active RA is, but about the comorbidities of anxiety, depression, and fibromyalgia. So in this particular analysis, retrospective analysis, a hundred and seventy three people, from Liverpool and, a hundred and four patients with RA from Mount Sinai. When they looked at the number of patients who have either no swollen or one swollen joints, it's seventy one to seventy five percent.

The number of patients who have a swollen joint count of greater than... Of two or greater, as twenty nine and twenty five percent. The number who were in, remission or LDA, forty two and forty nine percent. Those are numbers I began with. And the answer to the question is also provided by the MDHAC that says the number of people who, screen positive for anxiety, depression or fibromyalgia is forty six and thirty one percent in those two different cohorts.

The point being that you should be asking about anxiety and depression and poor sleep and features of fibromyalgia in every assessment of RA patients cause it will color the outcomes. You know, he starts out the report talking about despite having, you know, great effective therapies, you know, biologics, JAK inhibitors, and whatnot, and all these tools to assess disease, we don't often get to remission even our patients who we say are doing great. If you do a formal measure, find out, well, there's residual pain and residual activity. And his point is that you should worry about the big three that will take your patient down and ruin your drug responses and that is anxiety, depression, and fibromyalgia. You should follow the work of Ted Pincus and others at Rush.

I'm Jack Cush with RheumNow here in Orlando at ACR26.

Hello. My name is Runaalini Day. I am a rheumatology and internal medicine fellow from London in The UK, and I'm delighted to be reporting for RheumNow here in sunny Orlando for ACR twenty twenty six. So a question for you. If a patient with rheumatoid arthritis still has a high disease activity score, does that necessarily mean they need more immunosuppression?

What would you do? Abstract 2,808 looks at that exact question by defining a state of low inflammatory activity. So in this particular abstract, the researchers used a modified version of the DAS twenty eight, the SDI, and the CDI that excludes tender joint count and the patient's global assessment. They analyzed three trials involving nine sixty patients alongside a prospective cohort of more than 3,400 individuals. The proposed thresholds were below 1.4 for the modified DAS28, three or less for modified SDI, and two or less for the modified CDI.

So those are the thresholds for the modified scores and not the usual scores that we would calculate in clinic. In the cohort, forty four percent met the modified DAS28 target compared with thirty two percent in the conventional DAS28 cohort. Despite identifying more patients, the new target was associated with similarly low levels of X-ray progression. Patients who met it but still had high conventional scores more often had conditions such as osteoarthritis and mood disorders. So the question is what the score is actually telling us.

So when assessing disease activity, if pain and tenderness remain high but there is little swelling, we would assess for ongoing inflammation and look for other explanations before changing treatment. Ultrasound can also help when the clinical picture is uncertain. However, we must also acknowledge, and address the pain symptoms. So sometimes someone can have low inflammatory activity but still be struggling with, pain, fatigue, and disability and other, really quite troubling symptoms. Those need separate assessments and a treatment plan as well.

These modified targets could help us separate the decision to escalate immunosuppression from the wider task of helping someone feel and function better. Before changing a DMARD, we therefore need to understand what is driving the patient's symptoms, and that's what this abstract is helping us to understand better. If you'd like to know more about that particular abstract, it's 2808. And for more coverage from ACR twenty twenty six, don't don't forget to follow RheumNow. Thank you.

Hi. It's doctor Artie Cavanagh from University of California San Diego coming to you for RheumNow, and I'm at the ACR Convergence here in Orlando. I'm giving a perspective. My perspective is on comparative effectiveness and study design. So, so many therapies we have, so many of our drugs, agents, and treatment algorithms.

How do we know which is best? Well, we like to see data that's compared, ideally head to head in a single study, but there's other ways that we can look at some data. Several abstracts at this meeting have raised some intriguing questions in that regard. I'm going to talk about a couple of studies that look at the JAK and Ips, the Janus Kinase Inhibitors. There's...

Both of these studies actually are to be presented a little bit later on in the study, but the posters were up, the abstracts have been reviewed, so I'm gonna tell you what I'm going into there with the questions about. First is LB21, which was a study of durasitinib compared to tofacitinib, and that's in patients with rheumatoid arthritis. This is an abstract from China, and it's interesting because the data were really outstanding. Both drugs did well with very high ACR twenty fifty responses, even ACR 70 responses. The gerocitinib, which is a JAK1TYK2 inhibitor, seemed to do better.

Looking at the study design, it is interesting. It's head to head, but a number of the patients had been previously exposed to JAK inhibitors, even the tofacitinib, which is one of the arms. So you wonder how that may have impacted the results. Also, ninety percent of the patients had been on a TNF inhibitor. None of the patients were on methotrexate.

Really outstanding results, and certainly you want to see it reproduced in a more heterogeneous population. So intriguing, we love head to head. It was really fascinating that the groups were randomized almost completely identically, which we don't often see. There's another poster that I got to go see. It's twenty four zero seven, and this is a head to head study from Pakistan.

And the question is, the patients were assigned to tofacitinib or upadacitinib. In this case, the tofacitinib seemed to work a little bit faster. They did a rapid remission as one of the outcomes. But really, the key question is study design. How were the patients allocated to the different groups?

And that was an issue with the other abstract as well. How do you pick the patients who are going to get which therapy? Is it completely randomized? Is there some sort of patient preference or provider preference? Because that can impact the results.

So a lot of data still to come. This is the first day of the ACR convergence. This is doctor Arty Kavanagh reporting for RheumNow.

Hello. My name is Rinalini Day. I'm a fellow in rheumatology and internal medicine from London in The UK. I'm delighted to be reporting for RheumNow from here in Orlando for ACR twenty twenty six. So could GLP-1s improve outcomes for people with osteoarthritis and rheumatoid arthritis beyond their effects on weight and glucose control?

There are many abstracts being reported here at convergence on the use of GLP ones in inflammatory arthritis, and this is just one of the many abstracts which caught my attention. This is abstract one nine two four, and it examined hospital outcomes using The US inpatient sample from 2016 to 2023. So this analysis represented almost twenty three million, admissions involving osteoarthritis and four and a half million with rheumatoid arthritis. GLP one use was identified through coding and recorded in just over one in a thousand admissions. In osteoarthritis, recorded GLP one use was associated with thirty thirty one percent lower odds of knee replacement after adjustment for demographics and comorbidities.

So that's a really important outcome for people with osteoarthritis. The authors also reported lower in hospital mortality and shorter stays. For people with rheumatoid arthritis, in hospital mortality was naught point three four percent with recorded GLP one use compared with two point seven six percent without it. Hip and knee replacement in this population was also lower, and hospital stays were shorter. However, the adjusted rheumatoid arthritis estimates were not statistically significant.

So it's important to note that these are hospital admissions and not individual patients followed from starting their treatment. Lower odds of surgery during admission do not show that a GLP one drug prevented or delayed a future joint replacement. The key question is, can better treatment of obesity and metabolic disease improve longer term outcomes for people with conditions such as osteoarthritis and rheumatoid arthritis? For rheumatologists, we should be ensuring that obesity and diabetes are addressed alongside arthritis. These...

This includes discussing weight in a sensitive manner, helping patients access appropriate support, and coordinating care with, other teams such as primary care teams and weight management services. GLP one drugs should be considered for established indications, of course. In osteoarthritis, weight management should be discussed alongside treatment for pain and functional limitation and other patient reported outcomes. And in rheumatoid arthritis, obesity care should complement assessment of inflammation and appropriate DMARD treatments. Ultimately, patients need a plan that addresses both their arthritis and their metabolic health as well as their other comorbidities.

If you'd like to know more about this abstract, it's abstract one nine two four. And to find out more about everything going on about here in the ACR twenty twenty six convergence, do be sure to follow along on RheumNow. Thank you.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×